Home » Stocks » FMTX

Forma Therapeutics Holdings, Inc. (FMTX)

Stock Price: $37.50 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $37.00 -0.50 (-1.33%) Jan 15, 4:18 PM
Market Cap 1.64B
Revenue (ttm) 7.44M
Net Income (ttm) n/a
Shares Out 41.09M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $37.50
Previous Close $37.50
Change ($) 0.00
Change (%) 0.00%
Day's Open 35.81
Day's Range 35.31 - 37.75
Day's Volume 485,676
52-Week Range 32.95 - 51.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics provides a review of 2020 company highlights and an outline of anticipated 2021 milestones.

Business Wire - 1 week ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that renowned doctor Selwyn M. Vickers, M.D., has been elected to the company's board of directors.

Business Wire - 1 month ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the closing of an underwritten public offering of 6,095,000 shares of its common stock.

Business Wire - 1 month ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

Business Wire - 1 month ago

WATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics launches a proposed public offering of 4,600,000 shares of its common stock.

Business Wire - 1 month ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics presents clinical proof-of-concept data on FT-4202 in sickle cell disease at the 62nd ASH annual meeting.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces financial results for the third quarter ended September 30, 2020.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces EU Orphan Drug designation for FT-4202 for the treatment of sickle cell disease.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma announced that four abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma today announced that company management will participate in three upcoming investor conferences.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive top-line data from planned interim analysis of Phase 2 trial evaluating olutasidenib in acute myeloid leukemia.

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointments of two new vice presidents

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointment of Thomas G.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results for the second quarter ended June 30, 2020 and provides business update.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that Wayne A.I.

CNN Business - 6 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, IMRA, KROS, PCVX, RNA, RPTX, XBI, ZNTL
GuruFocus - 6 months ago

Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.

Other stocks mentioned: RPTX

About FMTX

Forma Therapeutics Holdings, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed t... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2020
CEO
Frank D. Lee
Employees
89
Stock Exchange
NASDAQ
Ticker Symbol
FMTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FMTX stock is "Strong Buy." The 12-month stock price forecast is 61.60, which is an increase of 64.27% from the latest price.

Price Target
$61.60
(64.27% upside)
Analyst Consensus: Strong Buy